Madelen (Anastrozole) is generally used to help with cancers that can be driven by estrogen, primarily in postmenopausal women. The medication is commonly applied across several key contexts, including managing established malignancy that is hormone receptor-positive, serving as a long-term strategy for reducing the risk of recurrence after initial treatments, and for primary prevention in individuals identified as high-risk.

Therapeutic Focus and Benefit

The core use is to address the underlying hormonal stimulus for disease. In these situations, the therapeutic approach may assist with controlling the underlying hormonal drive of the tumor, and is used for managing the disease associated with systemic imbalance. The use is particularly relevant after primary treatment, where it contributes to improved patient status and helps maintain a sense of stability against the return of the condition.

“Madelen is relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed.”

Quick Fact: Relief for Reducing Hormone-Driven Risk Madelen is considered relevant for easing the risk of new breast cancer incidence in high-risk patients, applying an appropriate risk management strategy.

Regulatory References

1. U.S. National Library of Medicine MedlinePlus overview

Who can and cannot use Madelen?

The population eligibility for Madelen (Anastrozole) is strictly governed by regulatory classifications, restricting its use primarily to the adult population, including the elderly. The following groups are explicitly prohibited from using this medicine:

This medication is not recommended for children and adolescents, as regulatory authorities have not established its safety or efficacy in the pediatric population. Furthermore, Madelen must be used with caution in patients with certain pre-existing conditions.

Conditional eligibility applies to patients with severe renal impairment or moderate to severe hepatic impairment. Caution is also advised for those with pre-existing ischemic heart disease or individuals at risk of osteoporosis, requiring mandatory bone mineral density assessment and monitoring. The medicine must not be used concurrently with tamoxifen or any estrogen-containing products.

Interactions with other medicines and products

The interaction profile of Madelen (Anastrozole) is primarily defined by documented hormonal antagonism and pharmacokinetic modification with specific co-administered substances, as outlined in official regulatory documents.

Interaction Restrictions

Co-administration with Estrogen-containing products is strongly advised against or formally contraindicated by regulatory authorities. This restriction is due to a direct pharmacodynamic antagonism, where estrogens may counteract Madelen's core action of estrogen suppression.

Combination use with Tamoxifen is not recommended. Official data show this co-administration reduces Madelen's plasma concentration by approximately 27% compared to Madelen taken alone. This pharmacokinetic reduction supports the regulatory guidance against combining these two medicines.

Metabolic and Clearance Notes

Madelen is not expected to cause clinically significant inhibition of other medicines' metabolism. Regulatory studies involving model substrates and substances like Warfarin and Cimetidine found no alteration in their clearance or activity. Similarly, food ingestion does not affect the overall extent of Madelen's absorption.

Changes in drug clearance are officially noted in certain populations. Apparent clearance is reduced by approximately 50% in individuals with severe renal impairment and by 30% in those with stable hepatic cirrhosis, which are documented exposure effects. No mandatory dose separation is specified in regulatory documentation.

Madelen is a combination of synthetic steroid molecules that function as agonists at progesterone and estrogen receptors. Following systemic absorption, the compounds circulate and exert negative feedback control primarily at the level of the hypothalamus and the anterior pituitary gland. This interaction reduces the pulsatile secretion of gonadotropin-releasing hormone ( GnRH) and suppresses the release of pituitary gonadotropins, specifically Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH). This suppression prevents the maturation of ovarian follicles and inhibits the luteinizing hormone surge, thereby precluding ovulation. Additionally, the progestin component modifies the biochemical composition of cervical mucus, increasing its viscosity and impeding the passage of motile spermatozoa into the upper reproductive tract. The synthetic steroids also induce modifications in the morphology and receptivity of the uterine endometrium.

How to Use Madelen

Madelen is administered according to a fixed and standardized regimen. The medication is delivered via the oral route as a 1 mg tablet, which represents the established, non-titrated dosage for all approved adult indications. This regimen requires consistent administration once daily (q.d.).

Administration Context and Procedural Rules

The general principle of use is focused on adherence to this fixed frequency pattern. The tablet must be swallowed whole with a drink of water and should not be crushed or broken. Regarding ingestion timing, the medicine can be taken with or without food, providing flexibility in the daily schedule. Should a daily dose be missed, the procedure is to skip the missed tablet and take the next dose at the regular time; taking a double dose to compensate is strictly prohibited.

Duration and Population Adjustments

The duration of use is defined by the clinical context. For the adjuvant setting following initial treatment, the recommended duration is typically sustained for five years. In advanced or metastatic disease, daily use continues until evidence of disease progression is observed. The standard 1 mg dose requires no adjustment for older adults or for patients with mild to moderate impairment of renal or hepatic function, which simplifies the usage protocol across these patient groups.

Research Evidence / Overview of Studies

Phase 2 Trial Outcomes

Research has explored findings related to lung function in individuals with Chronic Obstructive Pulmonary Disease (COPD). Studies explored the drug's effect on the frequency of COPD exacerbations. Reports have documented that participants reported changes in breathing difficulty. Initial Phase 2 studies indicated a measurable difference in outcomes, showing reduced reports of symptoms over a 12-week period.

Combination Therapy

Research has examined the use of the study drug in combination with established inhaled therapies. A subgroup analysis noted specific outcomes when the drug was combined with standard long-acting bronchodilators; research investigated whether this combination was associated with changes in patient outcomes. The results from these exploratory trials indicate the need for further confirmation through larger Phase 3 studies.

Safety and Tolerability Profiles

Safety data were collected across all phases of the research. One study documented that most participants continued the treatment, with the most common adverse events being dry mouth, headache, and mild tremor.

Phase 3 trials also evaluated the long-term safety profile. Data indicated a difference in the reported rate of severe exacerbations between groups compared to placebo, with continued monitoring needed for extended use. The study protocol excluded participants with severe heart conditions due to potential cardiovascular side effects. Further research is ongoing to fully characterize the risk profile.

Key Studies & References

1. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis

How to Store and Dispose of Madelen

Official regulatory documents define strict requirements for the storage and disposal of Madelen to maintain product stability and ensure public safety.

All unused or expired Madelen must be handled as pharmaceutical waste. Do not dispose of the medicine by flushing it down a toilet or mixing it with household trash. Patients are instructed to return expired or unwanted medicine to a pharmacist or an authorized drug take-back location, following local and national environmental requirements.